Plasma cell myeloma, characterized by clonally aberrant plasma cells that produce abnormal monoclonal Igs, is the most common indication for autologous hematopoietic progenitor cell transplantation (AHPCT) in North America. We observed appearance of new monoclonal gammopathies different from the original protein in the post-AHPCT setting and termed this condition 'secondary MGUS' (monoclonal gammopathy of undetermined significance). Hence, we performed a retrospective, single institution review of serum protein electrophoresis/immunofixation electrophoresis data in 92 AHPCT recipients from the period 2000 --2009. In all, 22 of 92 patients (24%) undergoing AHPCT met criteria for secondary MGUS. Contrary to previous studies, often referred to as 'abnormal protein banding,' we did not observe this condition as a favorable prognostic indicator in affected patients when compared with the control group (P ¼ 0.686). However, we did note that a subgroup of the study cohort who developed secondary MGUS after a prolonged latency (410 months) had an improved median OS compared with the remainder of the study cohort (75 months vs 41 months, P ¼ 0.005). As there have been significant advancements in understanding the pathobiology and clinical significance of MGUS, we believe that secondary MGUS merits dedication of resources for investigation to determine its true clinical relevance, prognostic value and pathophysiology.
INTRODUCTION
Plasma cell myeloma (PCM) is a malignant disorder characterized by the accumulation of BM plasma cells that produce a complete Ig or an Ig light chain. Clinical and genetic data show that almost all cases of PCM result from an asymptomatic pre-malignant disorder characterized by a proliferation of monoclonal postgerminal-center B cells in the BM. 1, 2 Until relatively recently, the prognosis for myeloma patients has been poor. Median survival before 1997 was B2.5 years. 3 Kumar et al. 3 reported a study of 2981 myeloma patients diagnosed and treated in the last decade, showing a 50% improvement in OS compared with the previous decade (44.8 vs 29.9 months; Po0.001). This change in outcome reflects the introduction of novel therapeutic agents, including immunomodulatory drugs and proteasome inhibitors, in addition to refinement of autologous hematopoietic progenitor cell transplant (AHPCT) protocols. 3, 4 AHPCT is now an integral part of standard care for PCM patients and is the most common indication for AHPCT in North America. 5 Greater numbers of PCM patients are surviving for longer periods and many are proceeding to AHPCT. Thereafter, practitioners evaluate AHPCT recipients for extended follow up periods for a variety of reasons, including consideration of post-transplant maintenance therapies. At our institution, during this follow up period, we noted that some AHPCT recipients developed new or additional serum Ig or Ig light chain disorders different from the original abnormality. We retrospectively studied this phenomenon, which we termed 'secondary MGUS' (monoclonal gammopathy of undetermined significance). Herein, we report the findings of 92 consecutive plasma cell myeloma patients who underwent AHPCT in a 9-year study period in order to characterize the frequency and clinical behavior of those patients who acquired secondary MGUS in the post-AHPCT setting.
MATERIALS AND METHODS

Patients and therapy
Between January 2000 and May 2009, 92 patients underwent AHPCT for PCM at University Hospitals Case Medical Center in Cleveland, OH, USA. The Institutional Review Board for Human Investigation granted approval for this retrospective study. All data were obtained via a retrospective chart review using the electronic medical record as well as paper charts. Myeloma staging was reported using the Durie-Salmon clinical staging system. 6 The SPEP (serum protein electrophoresis) studies were ordered with regularity after diagnosis of PCM and in follow up at post-AHPCT clinic as a surrogate for disease activity.
Our AHPCT protocol for hematopoietic progenitor cell mobilization and subsequent transplantation has been previously reported. 7 Briefly, blood cells were mobilized from patients who were treated uniformly with CY 4 g/m 2 i.v., filgrastim (Amgen, Thousand Oaks, CA, USA) 10 mg/kg once or twice daily s.c. (determined by resting-state blood CD34 þ cell concentration), and prednisone 2 mg/kg/day through mouth for 4 days. Apheresis was undertaken when blood CD34 þ cell count exceeded 10/mL. Filgrastim was continued until the last day of apheresis. A multi-lumen central venous apheresis catheter was placed either in the internal jugular or subclavian vein for hematopoietic cell mobilization and subsequent transplantation. The date of transplant was defined as day T ¼ 0 and all days were calculated from this metric. For those patients who underwent a tandem AHPCT, the latency period was measured starting at T ¼ 0 from the first transplantation. The conditioning regimen consisted of amifostine 740 mg/ m 2 i.v. on days T-2 and T-1 and melphalan 200 mg/m 2 i.v. on day T-1. All patients received filgastrim support from day T þ 1 until 3 consecutive days after blood neutrophil count 4500/mL.
Secondary MGUS identification
Patients who developed a secondary MGUS were identified using a review of all SPEP, immunofixation electrophoresis (IFE) and urine protein electrophoresis data. Once selected out, an in-depth patient chart, as well as an immunoelectrophoretic, data review was undertaken. The data and follow up were current through 1 May 2011. Any patient receiving allogeneic hematopoietic progenitor cell transplantation was excluded from this study to ensure a more homogenous cohort of patients. Serum IFE was performed using the HYDRASYS agarose gel electrophoresis apparatus by Sebia (Norcross, GA, USA), according to the manufacturer's instructions. Briefly, the proteins were first separated by electrophoresis on alkaline-buffered agarose gels. Individual antisera against IgG, IgA and IgM heavy chains, and k and l light chains were applied. The monoclonal proteins were identified following staining of the immunoprecipitates. IFE was performed at initial presentation and subsequently as indicated by SPEP results. A change in the monoclonal protein was defined as a change in either/both the heavy chain, light chain or by a change in gel migration. The latter was identified by serum IFE, which was distinct from the paraprotein detected at presentation of PCM. Figure 1 demonstrates a patient with multiple secondary gammopathies, which were detected in the post-AHPCT setting.
Statistical analysis
The time to development of secondary MGUS, or 'latency period,' was measured from the date of the first AHPCT (eight patients underwent tandem AHPCT) to date of development of secondary MGUS. OS was measured from the date of transplantation to the date of death and censored at the date of last follow-up for survivors. Survivor distribution was estimated using Kaplan --Meier's method and the difference of survival between the groups was examined by log-rank test or Wilcoxon test. 8 The effect of latency on OS was evaluated by Cox model. 9 The comparison of age between the two groups was made by Student's t-test. The association between two factor variables was examined by w 2 test. All tests are twosided and a P-valueo0.05 was considered statistically significant.
RESULTS
In all, 92 patients underwent AHPCT over the study period of more than 9 years. A total of 22 patients (24%) with PCM undergoing AHPCT developed secondary MGUS in their post-transplant course (Table 1) . Median age was 53.5 years and ranged from 39 to 68 years at time of first transplant; eight patients underwent a tandem or second AHPCT procedure. Nine patients (41%) developed only a single new monoclonal protein post-AHPCT, whereas five subjects acquired four or more new proteins after AHPCT. A total of 55% (N ¼ 12) developed secondary MGUS by 9.6 months, whereas in the remainder of the study cohort (N ¼ 10) the additional protein emerged after a prolonged median (range) latency period of 19.2 (11.4 --63.9) months, Figure 2 .
Our data showed no clear predilection for development of secondary MGUS based on age, gender or Durie-Salmon stage of PCM at presentation. A comparison of the 22 patients in the secondary MGUS cohort to the 70 unaffected control cohort showed no statistically significant OS difference between the two groups ( Figure 3 , P ¼ 0.334). We did note, however, that the time to onset of secondary MGUS influenced the OS as a function of time to onset. Figure 4 shows that patients who developed secondary MGUS at a prolonged latency (410 months after AHPCT) had a longer median OS when compared with those patients who experienced earlier onset (o10 months), that is, 75 months vs 41 months (P ¼ 0.005). original immunoprotein identified at diagnosis. This condition represents neither a new malignancy nor a disease recurrence. We have termed this incompletely understood phenomenon as secondary MGUS. In this nearly decade-long single institution analysis, we observed a 24% incidence of secondary MGUS in PCM patients undergoing AHPCT. OS did not differ between affected (N ¼ 22) and unaffected (N ¼ 70) patients (P ¼ 0.686), but in the subgroup (N ¼ 10) of secondary MGUS patients in whom the abnormal banding occurred beyond 10 months after AHPCT, median OS was longer (75 months vs 41 months). This latency period has not been previously described nor analyzed as prior studies describe secondary MGUS development at 1.8 --4.4 months after transplant (Table 2 ) and often as a transient phenomenon. 10 --16 Our small sample size and potential for leadtime bias, however, preclude drawing broad conclusions regarding this observation. The earliest reports of post-transplant, 'transient oligoclonal and monoclonal gammopathies', were noted specifically in the allogeneic transplant setting, although no PCM were reported in the series from Mitus et al. 17 This phenomenon occurred in more than half the patients and was strongly correlated with GVHD. 17 These authors hypothesized that the 'banding' was due to recapitulation of B-cell ontogeny or possibly due to T-cell dysfunction in the post-allogeneic transplant setting. A second small body of literature describes 'abnormal protein bands, ' analogous to what we describe as secondary MGUS, specifically in PCM patients in the post-transplant setting (Table 2 ). This phenomenon is noted at varying frequencies and has been reported to affect between 6.6% to 73% of PCM patients who have undergone either allogeneic or autologous transplant. 10 --16 This highly variable incidence could be attributed to a number of factors, including observer inconsistency, bias, differences in graft source and conditioning regimens, as well as technical and procedural variability, thus leading to differences in sensitivity of detection between institutions.
These same studies evaluating the clonal banding pattern of post-AHPCT PCM patients also indicated that this phenomenon was associated with favorable outcomes compared with those patients who did not demonstrate this 'banding' pattern. 10 --15 It should be noted that secondary MGUS is not necessarily a good prognostic marker. As shown in Table 2 , some previous studies only noted improved EFS (event free survival) or OS in the subgroups of the secondary MGUS cohorts. For example, Zent and co-workers 11 included only those who had survived 12 months after transplant, thus introducing selection bias into their outcome of improved OS. Additionally, Alejandre and colleagues 14 saw only improved OS in patients with 'oligoclonal banding' post AHPCT and not in patients with 'monoclonal banding.' Correspondingly, we noted that the subgroup with prolonged latency of 410 months showed improved OS. Only applies to the oligoclonal banding group; the monoclonal banding group showed no improvement in overall survival.
c Only seen in the subgroup with prolonged latency period to secondary MGUS410 months (n ¼ 9 patients).
We did not identify another etiology for the monoclonal gammopathies outside of secondary MGUS. Patient no. 8 was noted to have Rai Stage 0 CLL prior to tandem AHPCT and three patients (patients no. 4, no. 14, and no. 17) developed secondary MGUS after being diagnosed with biopsy-proven autologous GVHD. 7 Wadhera and associates 16 at the Mayo Clinic recently reported their experiences in 1942 PCM patients. Secondary MGUS was significantly more common in hematopoietic cell transplant recipients than in PCM subjects who had not received this therapy (22.7% vs 1.6%, respectively, Po0.001). The significance and mechanism of development of secondary MGUS in the posttransplant setting remain unknown. Common hypotheses include oligoclonal reconstitution of the immune system after conditioning with a myeloablative regimen, and impaired T-cell regulation of B-cell proliferation in the marrow after AHPCT. The former explains the early appearance of secondary MGUS; the latter may explain later appearance or persistence of secondary MGUS, as Tcell dysfunction that may persist for years after transplantation. A final consideration is that perhaps PCM patients are predisposed to developing clonal plasma cell disorders. As stated, Weiss et al. and Landgren and colleagues 1 reported that nearly all PCM is preceded by MGUS, often by many years. As PCM patients live longer, we need to continue to observe these cases of secondary MGUS to ascertain if the incidence of symptomatic PCM after AHPCT is associated with secondary MGUS.
Secondary MGUS is not an infrequently encountered phenomenon of which practitioners need to be aware. Further evaluation of the mechanism and etiology of this condition is indicated. Probing may shed light on understanding the post-AHPCT PCM disease process and outcomes as well as to elucidate alterations of host immunity.
